Hillsdale Investment Management Inc. Corcept Therapeutics Inc Transaction History

Hillsdale Investment Management Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$19.95 - $29.96 $19,950 - $29,960	1,000 Added 0.44%	226,400 $4.6 Million
Q3 2022 Nov 10, 2022	SELL	$24.7 - $29.12 $582,920 - $687,232	-23,600 Reduced 9.48%	225,400 $5.78 Million
Q2 2022 Aug 12, 2022	BUY	$17.33 - $25.3 $24,261 - $35,420	1,400 Added 0.57%	249,000 $5.92 Million
Q1 2022 Apr 28, 2022	BUY	$16.53 - $25.21 $4.09 Million - $6.24 Million	247,600 New	247,600 $5.58 Million
Q4 2020 Feb 09, 2021	SELL	$16.78 - $27.3 $3.11 Million - $5.06 Million	-185,400 Closed	0 $0
Q2 2020 Aug 11, 2020	BUY	$11.0 - $18.26 $2.04 Million - $3.39 Million	185,400 New	185,400 $3.12 Million
Q2 2018 Aug 13, 2018	SELL	$15.3 - $19.69 $1.23 Million - $1.58 Million	-80,300 Closed	0 $0
Q1 2018 May 14, 2018	SELL	$14.59 - $25.5 $145,900 - $255,000	-10,000 Reduced 11.07%	80,300 $1.32 Million
Q2 2017 Aug 14, 2017	BUY	N/A	90,300	90,300 $1.07 Million

403

84.3M

1.04M

1.33M

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $6.81B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Hillsdale Investment Management Inc., based on Form 13F filings with the SEC.

Stay updated on Hillsdale Investment Management Inc. with notifications on news.